Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.91 AUD | -1.00% | +0.13% | -6.81% |
Apr. 29 | Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% | MT |
Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.81% | 490M | |
-4.10% | 86.85B | |
+2.76% | 40.16B | |
-16.48% | 31.28B | |
+57.86% | 25.27B | |
-13.58% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-9.82% | 7.94B |
- Stock Market
- Equities
- CUV Stock
- News Clinuvel Pharmaceuticals Limited
- Clinuvel Reports Positive Results in SCENESSE Study